Orhan KIZILKAYAİ, Öznur AKSAKAL, Doğan ÖZCAN, Oktay İNCEKARA

Nazofarengeal karsinomlu 100 hastanın retrospektif analizi

Amaç: Bu retrospektiv çalışmanın amacı, nonmetastatik nazofarengeal karsinomlu 100 hastanın survi ve rekürrens paternini analiz etmekti. Gereç ve yöntem : 1991-2003 yılları arasında tedavi edilen 100 nazofarengeal karsinomlu hasta retrospektif olarak incelendi. 24'ü yalnız radyoterapi ile tedavi edilirken, 76'sına kombine model tedavi (cisplatin bazlı 2-4 kür neoadjuvant kemoterapi ve radyoterapi) uygulanmıştı. Nazofarengeal bölgeye 66-70 Gy, lenf nodlarına 50 Gy, servikal hastalık mevcut ise tutulan alana 15-20 Gy boost dozu verilmişti.Bulgular: AJCC 1997 evreleme sistemine göre, hastaların 20'si evre II, 47'si evre III, 33'ü evre IV'tü. Tüm hastalar skuamoz hücreli nazofarengial karsinom tanısı almıştı (18 WHO I-II, 82 WHO III). Minimum takip süresi 2 yıldı. İndüksiyon kemoterapisine yanıt oranı %75 (%13,2 tam ve %61,8 kısmi), yanıtsız olanların oranı (progresif hastalık) %7,9 ve stabil hastalık oranı %17,1'di. Radyoterapi sonrası başarısızlık oranı %53'tü. Bunların %56,6'sı lokoregional nüks, %28,3'ü lokoregional nüks ve uzak metastaz ve %15,1'i izole metastazdı. 5 yıllık genel sağ kalım yalnız radyoterapi verilenlerde %57,1, kombine tedavi verilenlerde %57,7 idi.Sonuç: İndüksiyon kemoterapisi nazofarengeal karsinomlu hastalarda tedavi sonuçlarını ve başarısızlık paternini değiştirmemiştir.

A retrospective study on 100 nasopharyngeal carcinoma patients

Objective: The aim of this retrospective study was to analyse the survival and recurrens patterns of 100 non-metastatic nasopharyngeal carcinoma patients. Materials and methods: A retrospective study in 100 nasopharyngeal carcinoma patients treated between 1991 and 2003 was performed. 76 received cisplatin based neoadjuvant chemotherapy for two or four courses prior to definitive radiotherapy and 24 were treated by radical radiotherapy alone. The total dose delivered to nasopharynx, lymph nodes and servical region (if affected) was 66-70 Gy, 50 Gy and 15-20 Gy respectively.Results: Twenty patients had stage II, 47 had stage III and 33 had stage IV disease (according to AJCC 1997 staging system). All patients were diagnosed as nasopharyngeal squamous cell carcinoma (18 WHO I-II and 82 WHO III). Minimum follow-up period was two years. Overall response after induction chemotherapy was 75% (with 13.2% complet response and 61.8% partial response). 13 patients had stable disease (17.1%), whereas 6 patients (7.9%) had progressive disease. Failure rate after radiotherapy was 53%. Locoregional recurrence was 56.6%, locoregional recurrence and distant failure was 28.3% and isolated distant failure was 15.1%. The five years overall survival was 57.1% for radiotherapy alone and 57.7% for the chemoradiotherapy.Conclusion: Induction chemotherapy neither improved the teratment outcome nor altered the failure patterns in patients with nasopharyngeal carcinoma.

PDF

___

1) Al-Sarraf M, Reddy MS. Nasopharyngeal carcinoma. Curr Treat Options Oncol 2002; 3:21-32.
2) Chan AT, Teo PM, Leung TW, Leung SF, Lee WY, Yeo W, Choi PH, Johnson PJ. A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1995; 33:569-577.
3) Cheng SH, Yen KL, Jian JJ, Tsai SY, Chu NM, Leu SY, Chan KY, Tan TD, Cheng JC, Hsieh CY, Huang AT. Examining prognostic factors and patterns of failure in nasopharyngeal carcinoma following concomitant radiotherapy and chemotherapy: impact on future clinical trials. Int J Radiat Oncol Biol Phys 2001; 50:717-726.
4) Cheng SH, Jian JJ, Tsai SY, Yen KL, Chu NM, Chan KY, Tan TD, Cheng JC, Leu SY, Hsieh CY, Huang AT. Long-term survival of nasopharyngeal carcinoma following concomitant radiotherapy and chemotherapy. Int J Radiat Oncol Biol Phys 2000; 48:1323-1330.
5) Chua DT, Ma J, Sham JS, Mai HQ, Choy DT, Hong MH, Lu TX, Min HQ. Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of two phase III trials. J Clin Oncol 2005; 23:1118-1124.
6) Chua DT, Sham JS, Wei WI, Ho WK, Au G, Choy D. Control of regional metastasis after induction chemotherapy and radiotherapy for nasopharyngeal carcinoma. Head Neck 2002; 24:350- 360.
7) Chua DT, Sham JS, Choy D, Lorvidhaya V, Sumitsawan Y, Thongprasert S, Wootiprux V, Cheirsilpa A, Azhar T, Reksodiputro AH. Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Asian-Oceanian Clinical Oncology Association Nasopharynx Cancer Study Group. Cancer 1998; 83:2270-2283.
8) Chua DT, Sham JS, Choy D, Kwong DL, Au GK, Kwong PW, Yau CC, Cheng AC, Wan KY. Patterns of failure after induction chemotherapy and radiotherapy for locoregionally advanced nasopharyngeal carcinoma: the Queen Mary Hospital experience. Int J Radiat Oncol Biol Phys 2001; 49:1219-1228.
9) Daniilidis J, Constantinidis J, Fountzilas G. Combined radiochemotherapy in locally advanced nasopharyngeal carcinoma HNO 2001; 49:732-738.
10) Farias TP, Dias FL, Lima RA, Kligerman J, de Sa GM, Barbosa MM, Goncalves FB Jr. Prognostic factors and outcome for nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg 2003; 129:794-799.
11) Fonseca E, Cruz JJ, Rodriguez CA, Gomez-Bernal A, Martin A, Sanchez P, Nieto A, Soria P, Vega MJ, Munoz A, Pardal JL. Neoadjuvant chemotherapy with continuous infusion of cisplatin and 5-fluorouracil, with or without leucovorin, for locally advanced nasopharyngeal carcinoma. J Infus Chemother 1996; 6:217- 220
12) Geara FB, Glisson BS, Sanguineti G, Tucker SL, Garden AS, Ang KK, Lippman SM, Clayman GL, Goepfert H, Peters LJ. Induction chemotherapy followed by radiotherapy versus radiotherapy alone in patients with advanced nasopharyngeal carcinoma: results of a matched cohort study. Cancer 1997; 79:1279- 1286.
13) Gruner A, Grabenbauer GG, Rodel C, Weidenbecher M, Martus P, Iro H, Sauer R. Nasopharyngeal carcinoma: only irradiation or simultaneous radiochemotherapy? Strahlenther Onkol 1999; 175:591-596.
14) Hareyama M, Sakata K, Shirato H, Nishioka T, Nishio M, Suzuki K, Saitoh A, Oouchi A, Fukuda S, Himi T. A prospective, randomized trial comparing neoadjuvant chemotherapy with radiotherapy alone in patients with advanced nasopharyngeal carcinoma.Cancer 2002; 94:2217-2223.
15) Hong S, Wu HG, Chie EK, Bang YJ, Heo DS, Kim KH, Sung MW, Park CI. Neoadjuvant chemotherapy and radiation therapy compared with radiation therapy alone in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1999; 45:901-905.
16) Huncharek M, Kupelnick B. Combined chemoradiation versus radiation therapy alone in locally advanced nasopharyngeal carcinoma: results of a meta-analysis of 1,528 patients from six randomized trials. Am J Clin Oncol 2002; 25:219-223.
17) Langendijk JA, Leemans CR, Buter J, Berkhof J, Slotman BJ. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. J Clin Oncol 2004; 22:4604-4612.
18) Ma BB, Chan AT. Recent perspectives in the role of chemotherapy in the management of advanced nasopharyngeal carcinoma. Cancer 2005; 103:22-31.
19) Ma J, Mai HQ, Hong MH, Min HQ Mao ZD, Cui NJ, Lu TX, Mo HY. Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol 2001; 19:1350-1357
20) Ozyar E, Gurkaynak M, Yildiz F, Atahan IL. Non-metastatic stage IV nasopharyngeal carcinoma patients: analysis of the pattern of relapse and survival. Radiother Oncol 2004; 72:71-77.
21) Rischin D, Corry J, Smith J, Stewart J, Hughes P, Peters L. Excellent disease control and survival in patients with advanced nasopharyngeal cancer treated with chemoradiation. J Clin Oncol 2002; 20:1845-1852.
22) Teo PM, Chan AT, Lee WY, Leung TW, Johnson PJ. Enhancement of local control in locally advanced node-positive nasopharyngeal carcinoma by adjunctive chemotherapy. Int J Radiat Oncol Biol Phys 1999; 43:261-271.